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Abstract
Daptomycin is a clinically important lipopeptide antibiotic that kills Gram-positive bacteria through 
membrane depolarization. Its activity requires calcium and the presence of phosphatidylglycerol in the 
target  membrane.  Calcium  and  phosphatidylglycerol  also  promote  the  formation  of  daptomycin 
oligomers,  which  have  been  assumed  but  not  proven  to  be  required  for  the  bactericidal  effect. 
Daptomycin shares substantial structural similarity with another lipopeptide antibiotic, A54145; the two 
have identical amino acid residues in 5 out of 13 positions and similar ones in 4 more positions. We 
here examined whether these conserved residues are sufficient for oligomer formation. To this end, we 
used fluorescence energy transfer and excimer fluorescence to detect hybrid oligomers of daptomycin 
and  CB-182,462,  a  semisynthetic  derivative  of  A54145.  Mixtures  of  the  two  compounds  indeed 
produced  hybrid  oligomers,  but  at  the  same  time  displayed  a  significantly  less  than  additive 
antibacterial  activity  against  Bacillus  subtilis.  The  existence  of  functionally  impaired  oligomers 
indicates that oligomer formation is indeed important for antibacterial function. However, it also shows 
that oligomerization is not sufficient; once formed, the oligomers must take another step in order to 
acquire  antibacterial  activity.  Thus,  the  amino  acid  residues  shared  between  daptomycin  and  CB-
182,462 suffice for formation of the oligomer, but not for its subsequent activation. 
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Introduction
The lipopeptide antibiotic daptomycin is used clinically against infections by Gram-positive bacteria, 
including strains of staphylococci and enterococci that are resistant to other antibiotics [1-3]. It binds to 
and  causes  depolarization  of  the  bacterial  cytoplasmic  membrane,  which  is  considered  to  be  the 
mechanism of its rapid bactericidal action  [4, 5]. Electron microscopy of daptomycin-exposed cells 
does  not  reveal  any discontinuity  of  or  morphological  change  to  the  lipid  bilayer  [6].  Both  this 
observation and the selective nature of the membrane permeability defect  [7] support the notion that 
daptomycin forms small, discrete membrane lesions. It was proposed earlier that these discrete lesions 
are formed by oligomeric assemblies of daptomycin molecules [5]. However, experimental evidence of 
oligomer formation has been obtained only recently  [8, 9], and direct proof of their involvement in 
membrane permeabilization is still lacking.
Daptomycin consists of 13 amino acids, including several nonstandard ones [10]. The ten C-terminal 
residues form a ring that is closed by an ester bond (Figure 1). The exocyclic N-terminal tryptophan 
carries a fatty acyl residue, which in the clinical compound is decanoic acid, although the length of this 
acyl tail is subject to variation in the natural compound. The same architecture occurs in the related 
antibiotic A54145  [11], and the two molecules also share significant sequence homology, with five 
identical residues and four more similar ones. We reasoned that testing the two molecules for their 
ability to form hybrid oligomers should provide information on the contributions of the conserved and 
the non-conserved residues, respectively, to the oligomerization process. 
The  experiments  were  performed  with  various  fluorescent  derivatives  of  daptomycin  and  of  CB-
182,462, a semisynthetic derivative of A54145 [12]. Our results readily demonstrate the formation of 
such hybrid oligomers, both on model membranes and on bacterial cells; therefore, the amino acid 
residues  conserved  between  daptomycin  and  CB-182,462  are  sufficient  for  oligomerization. 
Remarkably, however, the hybrid oligomers exhibit reduced antibacterial activity. The observation of 
oligomers with impaired antibacterial  activity shows, on the one hand, that the oligomer is  indeed 
involved in the antibacterial effect. On the other hand, it indicates that oligomer formation as such is 
not  sufficient  for activity.  The oligomer must  undergo some additional  event,  such as for example 
cooperative membrane insertion, in order to acquire bactericidal activity. 
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Materials and Methods
Synthesis and purification of NBD-CB-182,462 and of perylene-daptomycin. Unlabeled CB-182,462 
was kindly provided by Jared Silverman (Cubist Pharmaceuticals Inc., Lexington, MA, USA). Reaction 
of CB-182,462 with NBD-Cl (4-Chloro,7-nitro-2,1,3-benzoxadiazole; Fluka) and HPLC purification 
were performed as described before for NBD-daptomycin [8]. Molecular weight and homogeneity were 
confirmed by mass spectrometry on a Micromass Q-TOF Ultima GLOBAL mass spectrometer. The 
synthesis of perylene-daptomycin has been described as well [9].
Preparation of PC/PG large unilamellar vesicles (LUV). 1,2-Dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC) and 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DMPG) were purchased from 
Avanti Polar Lipids (Alabaster, AL, USA). Large unilamellar vesicles were prepared by polycarbonate 
membrane extrusion as described  [8]. HEPES buffer (20 mM, pH 7.4) containing 150 mM sodium 
chloride was used throughout. 
Steady-state  fluorescence  measurements  on PC/PG liposomes  and on bacterial  cells. Fluorescence 
emission spectra were acquired using a PTI QuantaMaster spectrofluorometer. Excitation wavelengths 
were 282 nm for tryptophan, 430 nm for perylene, and 465 nm for directly excited NBD fluorescence. 
Excitation and emission band passes were typically 2 nm but were occasionally adjusted in order to 
increase or reduce sensitivity. Unlabeled daptomycin and CB-182,462 or NBD-labeled CB-182,462 and 
perylene-labeled  daptomycin  were  applied  in  the  quantities  indicated  in  the  Results  section  to  the 
liposomes (200 or 250 μM total lipid) in HEPES/NaCl with calcium (5 mM). Samples were incubated 
for 5 or 10 minutes before acquisition of emission spectra, and in some instances measured repeatedly 
after longer time intervals as indicated. 
For fluorescence measurements on bacteria, cells from a fresh overnight culture of  Bacillus subtilis 
ATCC 1046 were harvested and repeatedly washed with HEPES/NaCl buffer by centrifugation in a 
table-top centrifuge. The pelleted cells were resuspended in approximately 20 volumes of buffer. Of the 
resulting cell suspension, 150 μl were incubated in the presence of CaCl2 (5 mM) for 10 minutes with 
the amounts of labeled or unlabeled daptomycin and CB-182,462 stated in the Results section. The 
cells  were again washed repeatedly by centrifugation with HEPES/NaCl/CaCl2,  resuspended in the 
same buffer and measured as described above for liposome samples. 
Antibacterial activity of daptomycin and CB-182,462. Overnight cultures of  Bacillus subtilis ATCC 
1046 were grown at 37 °C in LB broth. Daptomycin and CB-182,462, alone or combined in various 
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ratios, were serially diluted in LB broth supplemented with 5 mM CaCl2.  Each serial  dilution was 
inoculated with 1% by volume of the  Bacillus subtilis overnight culture, and the culture tubes were 
incubated with shaking at 37°C overnight. Growth was evaluated visually by turbidity. Growth and 
sterility controls were included in each experiment. 
Results
Oligomerization of CB-182,462 on liposome membranes. We have previously shown that daptomycin 
forms oligomers on model membranes and bacterial cells [8, 9, 13]. While the similarity between the 
two compounds suggests that CB-182,462 should do the same, this has not been directly demonstrated. 
Therefore, a fluorescently labeled derivative was prepared with nitrobenzoxadiazole (NBD) attached to 
its unique free amino group (Figure 1). While the absorption of NBD is highest around 470 nm, there is 
a smaller absorption peak around 340 nm [14] that overlaps the fluorescence emission spectrum of 
tryptophan. This allows the detection of FRET between the tryptophan of unlabeled CB-182,462 and 
the NBD-labeled derivative. In the experiment shown in Figure 2A, the two species were mixed before 
application  to  PC/PG  liposomes  in  the  presence  of  calcium.  The  tryptophan  fluorescence  of  the 
unlabeled molecules is very strongly reduced by FRET, which indicates a close association of the two 
species. FRET is still observed, but to a lesser extent, when the two species are applied sequentially. 
Under these conditions, the labeled molecules and the unlabeled ones should undergo oligomerization 
separately, and therefore FRET will only occur between, but not within oligomers, which accounts for 
the reduced extent of FRET.
NBD exhibits concentration-dependent self-quenching [15]. The local concentration of NBD is higher, 
and  therefore  quenching is  more  pronounced,  in  pure  NBD-CB-182,462 oligomers  than  in  hybrid 
oligomers formed from a mixture of the NBD-labeled compound and an excess of the unlabeled one 
(Figure 2B). The results from both FRET and self-quenching experiments are completely analogous to 
our previous observations with daptomycin [8].
Formation of daptomycin/CB-182,462 hybrid oligomers on liposomes. The intrinsic fluorescence of 
tryptophan also overlaps the absorption spectrum of kynurenine, which in daptomycin causes virtually 
complete FRET from tryptophan to kynurenine  [16]. FRET between tryptophan and kynurenine can 
also  be  used  to  detect  formation  of  hybrid  CB-182,462/daptomycin  oligomers.  When  a  premixed 
sample of the two is applied to PC/PG liposomes, the tryptophan fluorescence of CB-182,462 is largely 
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suppressed by FRET (Figure 3A). Again, sequential application reduces FRET, which is consistent with 
formation of separate oligomers.
While daptomycin oligomers are largely stable on a time scale of one or a few hours  [8], it seems 
possible that hybrid oligomers of CB-182,462 might be less stable. In the experiment shown in Figure 
3B,  a  sample  prepared  by  sequential  application  of  the  two  antibiotics  was  incubated,  and  the 
fluorescence emission measured repeatedly after  various  time intervals.  While  the extent  of FRET 
increases slightly with time, it remains much lower than that observed with a premixed sample after 60 
minutes. This suggests that the rate of subunit exchange between oligomers is low, and oligomers are 
largely stable on the time scale of the experiment.
Formation of hybrid oligomers on bacterial cells. While PC/PG membranes are a useful model to 
observe the activity of daptomycin and CB-182,462, the lipid composition of bacterial membranes is 
different, and it is therefore pertinent to examine the formation of hybrid oligomers on bacterial cells as 
well. Due to the abundance of tryptophan in bacterial proteins, the intrinsic tryptophan fluorescence of 
CB-182,462 could not be used in these experiments; however, two alternative approaches allowed for 
the detection of hybrid oligomers on  Bacillus subtilis cells. Firstly, the concentration-dependent self-
quenching of NBD in NBD-labeled CB-182,462 can be inhibited not only by unlabeled CB-182,462 
but also using unlabeled daptomycin (Figure 4A). Secondly,  the formation of perylene excimers in 
oligomers  of  perylene-labeled  daptomycin  [9] is  suppressed  by  both  unlabeled  daptomycin  and 
unlabeled CB-182,462 (Figure 4B). Between the two experiments, it is evident that both the labeled 
and the unlabeled forms of daptomycin and CB-182,462 are capable of hybrid oligomer formation on 
bacterial cell membranes. 
Antibacterial activity of daptomycin/CB-182,462 mixtures. If two different drugs act independently but 
share the same target and mode of action, their mixtures will display additive effectiveness. This can be 
detected in an isobologram [17]. In such a graph, the concentrations of the two drugs in question are 
varied independently, and lines are drawn to connect equieffective dosages of various combinations. If 
the two drugs in question indeed behave additively, the equieffective dosages of all mixtures will fall 
on a straight line that connects the equieffective dosages of the two pure drugs. 
Figure 5 shows an isobologram for the minimum inhibitory concentrations (MICs) of daptomycin and 
CB-182,462. It  is  clear  that  the MICs deviate  from such an ideal  straight  line.  With the mixtures, 
greater than additive dosages are required to reach the MIC, indicating that the two drugs inhibit one 
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another. The apex of mutual inhibition occurs at equimolar ratio. While any binary mixture should 
produce a distribution of oligomers that vary with respect to both the fractions of the two antibiotics 
incorporated  and  the  positions  within  the  oligomer  occupied  by  each,  an  equimolar  ratio  should 
maximize the extent of scrambling and minimize the residual fractions of homogeneous oligomers. The 
observation that mutual inhibition is strongest at this ratio therefore supports the notion  that hybrid 
oligomers have impaired antibacterial activity. 
Discussion
In previous studies, it was shown that daptomycin forms oligomers on PG-containing membranes [8, 
9],  and  that  the  oligomers  have  a  stoichiometry  of  approximately  6–7  subunits  [13].  A role  of 
membrane-associated oligomers in the antibacterial activity of daptomycin has widely been assumed 
and accepted as plausible [5]; however, direct experimental evidence has been lacking. The mutual 
inhibition between daptomycin and the semisynthetic homologous lipopeptide CB-182,462 reported in 
this study constitutes the first such evidence; for if each individual monomer contributed independently 
and  proportionally  to  the  antibacterial  action,  combinations  of  the  two  antibiotics  should  display 
additive activity. In addition, however, the reduced antibacterial activity of hybrid oligomers also shows 
that oligomer formation as such is not sufficient for the antibacterial effect. One must therefore assume 
that the oligomer, once formed, has to undergo an additional step to acquire bactericidal activity. A 
similar  functional  sequence  exists  with  many  pore-forming  protein  toxins,  such  as  for  example 
Staphylococcus  aureus α-toxin  [18,  19],  anthrax  toxin  protective  antigen  [20]  and the  cholesterol-
dependent cytolysins of Gram-positive bacteria [21], all of which first assemble into oligomers atop the 
target  membrane  before  cooperatively  inserting  into  and  permeabilizing  it.  By  analogy,  one  may 
hypothesize that the oligomers of daptomycin and related antibiotics also undergo such a cooperative 
membrane insertion (Figure 6); however, the structural correlate of oligomer activation clearly needs 
further experimental study. The same applies to the functional roles of individual amino acid residues 
in  the  daptomycin  molecule.  While  our  study makes  an  initial  distinction  between two functional 
groups of residues – namely, the ones shared between daptomycin and CB-182,462, which suffice for 
oligomerization, and those not shared between the two molecules, at least some of which are required 
for oligomer activation – this level of resolution is clearly inadequate for construction of a detailed 
structural and functional model of the formation and activation of the oligomer. Studies with additional 
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synthetic or genetically engineered [22, 23] molecular variants of daptomycin may help to address this 
question. 
The high degree of specificity in the mutual interaction of the subunits within the daptomycin and CB-
182,462 oligomers agrees with the considerable stability of the oligomers; even the hybrids, which one 
might expect to be less stable than the homogeneous oligomers, appear mostly stable on a time scale 
longer than required for exercising the antibacterial effect. Daptomycin has been likened to the large 
and  structurally  diverse  functional  family  of  antibacterial  peptides  [24,  25].  However,  with  most 
antibacterial peptides, oligomer formation seems to be rather fleeting and transient, or at least more 
readily reversible [26-29] than with daptomycin and CB-182,462. It appears possible, therefore, that 
pore-forming  protein  toxins  provide  a  more  useful  and  valid  paradigm than  typical  antimicrobial 
peptides to understand daptomycin's mode of pore formation. 
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Legends to Figures
Figure 1: Structures of daptomycin and of CB-182,462 and of their labeled derivatives used in this 
study. Arrows indicate amide or ester bonds, in C to N or C to O direction. In perylene-daptomycin, a 
perylene-butanoyl residue replaces the N-terminally attached decanoyl residue found in daptomycin. 
CB-182,462 is  a semisynthetic derivative of the natural compound A54145, in which the naturally 
occurring N-terminally linked fatty acyl residue is replaced by a substituted carbamyl residue. In NBD-
CB-182,462, a nitrobenzoxadiazole group is attached to the free amine in the side chain of D-lysine. 
Abbreviated names for non-standard amino acids: Orn, ornithine; MeOGlu, γ-methoxy-glutamate; kyn, 
kynurenine; HO-Asn,  β-hydroxy-asparagine; MeOAsp,  β-methoxy-aspartate. The two residues whose 
intrinsic fluorescence was used in some of the experiments, tryptophan in CB-182,462 and kynurenine 
in daptomycin, are set in boldface. Note that, in addition to the sequence similarity, the same positions 
are occupied by D- and L-amino acids in both molecules.
Figure 2: Formation of CB-182,462 oligomers on PC/PG liposomes. NBD-labeled CB-182,462 (0.96 
µM) and unlabeled CB-182,462 (4.8 µM), alone or combination, were incubated with PC/PG (1:1, 200 
µM total  lipid)  liposomes  in  the  presence  of  calcium (5  mM).  A:  Tryptophan  fluorescence  upon 
excitation at 282 nm. NBD-CB-182,462 has virtually none, due to FRET from tryptophan to NBD. 
When the two compounds are mixed before application to liposomes, the tryptophan fluorescence is 
more  strongly quenched  than  when they are  applied  separately with  a  time  interval  of  5  minutes 
between both applications. This is consistent with the formation of hybrid oligomers in the first case 
but  mostly  segregated  oligomers  in  the  second.  The  emission  of  NBD  was  not  scanned  in  this 
experiment  because  it  overlaps  the  secondary  maximum  of  the  excitation  wavelength.  B:  Self-
quenching of NBD-CB-182,462. Addition of unlabeled CB-182,462 before application to the PC/PG 
liposomes increases the fluorescence intensity of NBD-CB-182,462 upon direct excitation of NBD at 
465  nm,  indicating  that  the  latter  is  subject  to  self-quenching  in  homogeneous  oligomers.  If  the 
unlabeled CB-182,462 is added 5 minutes after the NBD-labeled sample,  it  has little effect on the 
extent of quenching. 
Figure 3:  Formation of hybrid oligomers of native CB-182,462 and daptomycin on liposomes.  A: 
When both compounds (2  μM each) are mixed before addition to PC/PG liposomes (250  μM total 
lipid) and calcium (5 mM), the tryptophan fluorescence of CB-182,462 is strongly reduced by FRET, 
and the kynurenine emission of daptomycin (around 445 nm) is  increased.  The extent of FRET is 
12
smaller when one compound is applied to the liposomes 5 minutes after the first one.  B: Extended 
incubation of a sequentially prepared sample. The extent of FRET increases slightly with time, but after 
60 minutes still  does not approach that of a premixed sample, indicating that daptomycin and CB-
182,462 mostly do not reassemble into hybrid oligomers within this time period. Thin dotted lines 
represent several time points between 5 and 60 minutes. 
Figure  4:  Formation  of  hybrid  CB-182,462  oligomers  on  Bacillus  subtilis cell  membranes.  A: 
Alleviation of NBD-CB-182,462 self-quenching by unlabeled CB-182,462 or daptomycin. NBD-CB-
182,462 (4 µM), alone or premixed with unlabeled CB-182,462 or daptomycin (20 µM), was incubated 
with  Bacillus subtilis ATCC 1046 cells in the presence of calcium (5 mM). After incubation for 10 
minutes,  the cells  were washed repeatedly by centrifugation,  re-suspended in buffer,  and the NBD 
fluorescence measured upon excitation at 465 nm.  B:  Inhibition of excimer formation by perylene-
daptomycin by unlabeled daptomycin or CB-182,462. Perylene-daptomycin monomers emit maximally 
at 455 nm, whereas the excimers emit maximally at about 525 nm [9]. Concentrations of labeled and 
unlabeled compounds, and other conditions as in A. 
Figure 5:  Mutual  inhibition  of  bactericidal  action  between  daptomycin  and  CB-182,462.  Bacillus  
subtilis ATCC 1046 was pre-grown in LB broth and inoculated 1:100 into LB broth supplemented with 
calcium (5 mM) and either or both antibiotics as indicated. The data points represent the MIC values 
determined in two independent representative experiments. The dotted line (partly covered) represents 
the expected relationship for additive drug action. 
Figure 6: Hypothetical model for daptomycin action. Membrane binding (1) precedes oligomerization 
(2),  which  in  turn  must  be  followed  by  membrane  insertion  (3)  in  order  to  produce  functional 
membrane  lesions  (top).  In  mixtures  of  daptomycin  and  CB-182,462  (bottom),  oligomerization  is 
preserved, but membrane insertion is disrupted.
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